Meeting
2023 ASCO Quality Care Symposium
Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.
Authors
Steven Gilmore
U.S. Oncology/McKesson Specialty Health, The Woodlands, TX
Steven Gilmore, Victoria Handy, Melissa Carroll, Aimee Ginsburg, Shannon Hough
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Decision Support Tools
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 509)
DOI
10.1200/OP.2023.19.11_suppl.509
Abstract #
509
Poster Bd #
K12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).
First Author: Adeola Y. Makinde
Poster
2023 ASCO Annual Meeting
Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting.
First Author: Sudipto Mukherjee
Poster
2022 ASCO Annual Meeting
Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
First Author: Abhishek Avinash Mangaonkar
Poster
2020 ASCO Quality Care Symposium
Evaluating compliance of NCCN cancer and chemotherapy-induced anemia guidelines in a community healthcare setting.
First Author: Jamie Haber